| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
The enzyme acetylcholinesterase(IC50= 79 μg/mL )
Acetyllovastatin targets HMG-CoA reductase, the rate-limiting enzyme in the mevalonate pathway of cholesterol synthesis. It acts as a competitive inhibitor, binding to the active site of the enzyme and blocking its interaction with the substrate HMG-CoA. This inhibition leads to a reduction in the production of mevalonate and subsequent downstream products, including cholesterol and other isoprenoids. By lowering cholesterol production in the liver, Acetyllovastatin helps reduce total cholesterol, LDL cholesterol, and triglycerides while potentially increasing HDL cholesterol. It also presents a moderate inhibitory effect against the enzyme acetylcholinesterase with an IC50 of 79 μg/mL. |
|---|---|
| ln Vitro |
In vitro, Acetyllovastatin functions as a competitive inhibitor of HMG-CoA reductase, effectively reducing cholesterol synthesis in cell-based assays. It has been shown to lower cholesterol production in hepatocyte cell lines. Quantitative in vitro activity data, such as its IC50 for HMG-CoA reductase inhibition, is not detailed in the publicly available sources. However, as a lovastatin derivative, it is expected to have a similar potency. It also exhibits a moderate inhibitory effect against acetylcholinesterase with an IC50 of 79 μg/mL.
|
| ln Vivo |
In vivo, Acetyllovastatin is expected to reduce serum cholesterol levels by inhibiting HMG-CoA reductase in the liver. As a derivative of lovastatin, its in vivo efficacy and pharmacokinetic profile are likely similar to those of the parent drug. However, specific in vivo data for Acetyllovastatin itself is limited, as it is primarily used as a research tool and analytical standard. Its primary application is in studies of cholesterol metabolism and as a reference compound in analytical method development for statins.
|
| Enzyme Assay |
For in vitro cell-free assays, the inhibitory activity of Acetyllovastatin against HMG-CoA reductase can be measured using a standard enzyme activity assay. The assay involves incubating varying concentrations of Acetyllovastatin with purified HMG-CoA reductase enzyme, its substrate HMG-CoA, and the cofactor NADPH. The enzyme activity is monitored spectrophotometrically by measuring the decrease in absorbance at 340 nm, which corresponds to the oxidation of NADPH. The IC50 value, representing the concentration required to inhibit 50% of the enzyme activity, is calculated from a dose-response curve. Its moderate inhibitory effect against acetylcholinesterase can be assessed using a similar in vitro enzyme assay with a specific substrate.
|
| Cell Assay |
For cellular assays, the effect of Acetyllovastatin on cholesterol synthesis can be assessed in hepatocyte cell lines, such as HepG2 cells. Cells are treated with various concentrations of Acetyllovastatin for a defined period (e.g., 24-48 hours). The level of cholesterol synthesis is measured by incorporating a radiolabeled precursor, such as [14C]acetate, into cellular lipids, followed by lipid extraction and scintillation counting. Alternatively, the levels of total cholesterol and LDL cholesterol in the cell culture medium can be measured using enzymatic assays. The IC50 for inhibition of cholesterol synthesis can be determined from these experiments.
|
| Animal Protocol |
For in vivo studies, Acetyllovastatin could be administered orally to animal models of hypercholesterolemia, such as high-fat diet-fed hamsters or genetically modified mice (e.g., ApoE knockout mice). Blood samples are collected at various time points to measure serum lipid profiles, including total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides. The compound's efficacy in lowering cholesterol is determined by comparing the lipid levels in treated animals to those in a control group. Its effect on liver HMG-CoA reductase activity can also be assessed by preparing liver microsomes and measuring enzyme activity ex vivo.
|
| ADME/Pharmacokinetics |
Acetyllovastatin has a molecular formula of C26H38O6 and a molecular weight of 446.58 g/mol. Its CAS number is 81189-92-6. It is typically supplied as a powder. For in vitro studies, it is dissolved in DMSO to prepare stock solutions. For in vivo administration, it can be formulated in suitable vehicles. Storage is recommended at -20°C, protected from light. Its purity is typically >98% for research use. As a synthetic compound, its properties are well-defined.
|
| Toxicity/Toxicokinetics |
No detailed toxicity data is publicly available. As a statin derivative, potential toxicities may include hepatotoxicity, myopathy, and others typical of HMG-CoA reductase inhibitors. Standard toxicological studies would be required for drug development. In vitro cytotoxicity assays in hepatocyte cell lines are typically performed to assess its safety profile.
|
| References | |
| Additional Infomation |
Acetyllovastatin is a research-grade compound and is not approved for any therapeutic use. It serves primarily as a valuable pharmacological tool and a reference standard for studying cholesterol metabolism and the mechanism of statin action. Its mechanism of action involves the competitive inhibition of HMG-CoA reductase, leading to reduced cholesterol synthesis. It is also used as an intermediate in the chemical synthesis of other statin derivatives. No clinical trials have been reported for this compound.
|
| Molecular Formula |
C26H38O6
|
|---|---|
| Molecular Weight |
446.57600
|
| Exact Mass |
446.267
|
| CAS # |
81189-92-6
|
| PubChem CID |
90477402
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
4.766
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
32
|
| Complexity |
768
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
O([C@H]1C[C@@H](C)C=C2C=C[C@@H]([C@@H]([C@@H]12)CC[C@H]1OC(=O)C[C@H](OC(=O)C)C1)C)C(=O)[C@@H](C)CC
|
| InChi Key |
OYNSFDWALRRTFU-QQVNEASTSA-N
|
| InChi Code |
InChI=1S/C26H38O6/c1-6-16(3)26(29)32-23-12-15(2)11-19-8-7-17(4)22(25(19)23)10-9-20-13-21(30-18(5)27)14-24(28)31-20/h7-8,11,15-17,20-23,25H,6,9-10,12-14H2,1-5H3/t15-,16-,17-,20+,21+,22-,23-,25-/m0/s1
|
| Chemical Name |
[(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-acetyloxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] (2S)-2-methylbutanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 250 mg/mL (~559.81 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.66 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.66 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2392 mL | 11.1962 mL | 22.3924 mL | |
| 5 mM | 0.4478 mL | 2.2392 mL | 4.4785 mL | |
| 10 mM | 0.2239 mL | 1.1196 mL | 2.2392 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
